Cancer Research: 5 Reasons You Should Apply
Free lab space: provisions, access to mouse study and technicians
Mentorship: Experienced scientific team with commercial expertise and successful serial biohealth entrepreneur and team
Prime location in the center of the MD Biohealth corridor
$10,000 a month in support: $5,000 cash/$5,000 “in-kind”
No strings attached: no equity participation or IP rights required
Immunomic Therapeutics is committed to providing a workplace that bolsters scientific ideas. The Cancer Discovery Incubator will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.
Medigene AG (http://www.medigene.de) (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus like particles (AAVLPs) technology to the Swedish biotech company 2A Pharma AB, located in Malmö, Sweden. Under the terms of the agreement, Medigene is eligible to receive clinical, regulatory and commercial milestone payments in addition to royalties on net sales of future AAVLP products by 2A Pharma AB. Further financial details were not disclosed.
MaxCyte, Inc. announced today a strategic collaboration with leading academic research institution, Washington University in St. Louis (“Washington University”) to advance next-generation Chimeric Antigen Receptor (CAR)-based cell therapies for acute myeloid leukemia (AML).
MaxCyte and Washington University will develop unique immunotherapy drug candidates, based on MaxCyte’s proprietary cell engineering platform technology, CARMA.
This collaboration builds on MaxCyte’s efforts with The Johns Hopkins Kimmel Cancer Center around pre-clinical development of CAR therapy for solid cancers.
The University of Maryland will be a key partner in a new institute to advance U.S. leadership in pharmaceutical manufacturing that was announced by U.S. Secretary of Commerce Penny Pritzker on Friday, December 16, 2016. The National Institute for Innovation of Manufacturing Biopharmaceuticals (NIIMBL) will be the 11th Manufacturing USA Institute, and includes the University of Maryland, College Park and the University of Maryland, Baltimore. A team of more than 150 companies, educational institutions, nonprofits and state governments will operate NIIMBL under a newly formed nonprofit.
Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic Therapeutics”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy. ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform. A Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts has been initiated.
Sometimes lab research leads to a discovery that’s commercially viable enough to start a company. But for scientists with little business experience, making the jump to the private sector can be intimidating without support. In an effort to address this issue, the National Institute of Standards and Technology (NIST) has partnered with the Maryland Technology Development Corporation (TEDCO) (link is external) to award a new round of N-STEP grants, which support early-stage entrepreneurs in ways that other grants do not.
MdBio Foundation is hiring a team of enthusiastic individuals to operate the Verizon Innovative Learning explorer lab, a custom designed 45-foot bus that will travel to middle schools in the Washington, DC metropolitan area. In addition to providing instruction to middle school students aboard the bus, the team will also assist in the development of associated curriculum, coordinating school visits, and moving and placement of the vehicle.
The explorer lab is currently being built in Burbank, California and will travel across the United States for a “road show.” The road show will include a series of school visits and PR events between March and August 2017. In August 2017, the explorer lab will arrive in Washington, DC and will serve the DC Public School system for the 2017/2018 school year.
Formed in 1997, the Greater Rockville Partnership, now Rockville Economic Development, Inc. has evolved and grown to be an organization that has helped thousands of businesses and entrepreneurs in the City of Rockville. And we are so excited to hit 20 years of support and growth that we are going celebrate ALL YEAR LONG!
We have events and promotions planned throughout the year including our Business Appreciation Week, the REDI Commercial Broker Breakfast , the REDI Resource Meet up (R2M), as well as special 20th Anniversary events —you won’t want to miss any of them.
We are also offering 20th Anniversary sponsorship opportunities for companies looking for exposure by supporting our events throughout the year. If interested, you can contact Michael Steifvater via email or 301.315.8096.
The NHLBI’s Strategic Vision rests on four mission-driven goals that will benefit from sustained Institute focus. Eight objectives organize the 132 Research Priorities.
Facebook’s shadowy Building 8 research team needs help from academia to invent futuristic hardware. But today’s pace of innovation doesn’t allow for the standard 9-12 month turnaround time it takes universities to strike one-off research partnerships with private companies.
“Population Health, Privacy, Security. The Ultimate Balancing Act!”
January 19, 2017 4pm – 8pm
Governor Calvert House, 58 State Circle Annapolis, Maryland
Maryland Health Information Management Systems Society (MDHIMSS) is pleased to announce our 10th Annual Advocacy event being held in Annapolis, Maryland on Thursday, January 19, 2016 at Governor Calvert House from 4-8pm. This event focuses on balancing the need for information exchange for Population Health and responsibility to protect and secure that information. In addition to legislative updates a panel discussion and technology showcase will be on display.
Boston Scientific has made a name for itself with devices that are implanted into the body to prevent heart attacks. But through its Connected Patient Challenge, launched last month, the company is looking to get more involved in the kind of preventative medicine that’s based on the data generated by doctors, patients and the growth of wearable devices.
The healthcare industry’s transition toward value-based care is forcing providers to adopt new and emerging business models in lieu of traditional fee-for-service payment. At their core, these business models have the principle of value-based reimbursement, in which providers must meet certain quality care standards while controlling costs in order to get paid.
Cascadia Capital’s healthcare team contemplates the outlook for 2017, we believe the future of the industry will be affected by the agenda of the new administration. Where we believe this will have significant impact is on expense containment and prioritization of the wellness agenda.
Headquartered in Hayward, California, Intarcia Therapeutics is a force to be reckoned with in the biotech world. It has raised over $1 billion in total equity funding and recently acquired Phoundry Pharmaceuticals for an undisclosed amount.
It hasn’t gone public.
The year 2016 presented the world with a number of big surprises. Some positive, some negative, depending on whom one asks. Here at Medgadget, 2016 will be remembered for many amazing and pleasantly unexpected medical technology developments, many of which are foreshadowing cures for spinal cord injuries, effective treatment of diabetes, new ways to fight heart disease, and many other long sought-after medical solutions. Virtual and augmented reality systems, new imaging techniques, and innovative delivery approaches are changing the way doctors learn and take care of patients.
Superflex, a “powered” clothing startup that was spun out of SRI International, the well-known robotics nonprofit, announced earlier this week that it has raised $9.6 million in a Series A round of funding.
The Menlo Park, California-based company is developing a lightweight, connected apparel that can be worn underneath regular clothing. It’s called “powered” because integrated electric circuits throughout the apparel act as muscles providing strength and mobility to the body’s actual muscles and joints.
New research suggests it is possible to slow or even reverse aging, at least in mice, by undoing changes in gene activity—the same kinds of changes that are caused by decades of life in humans. By tweaking genes that turn adult cells back into embryoniclike ones, researchers at the Salk Institute for Biological Studies reversed the aging of mouse and human cells in vitro, extended the life of a mouse with an accelerated-aging condition and successfully promoted recovery from an injury in a middle-aged mouse, according to a study published Thursday in Cell.
Michael Lewis’s 2003 book, Moneyball — later made into a movie starring Brad Pitt — tells the story of how predictive analytics transformed the Oakland Athletics baseball team and, eventually, baseball itself. Data-based modeling has since transcended sport. It’s used in hiring investment bankers, for example. But is academe really ready for its own “moneyball moment” in terms of personnel decisions?
